Saline, QCZ484 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-01-29 in 4mo
ESTIMATED |
READOUT
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive P
Phase 2 · Hypertension |
NVS NOVARTIS AG | Saline, QCZ484 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-10-01
Sponsor-projected date — can change
|